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Objective: To compare the IVF outcomes of mild ovarian stimulation with conventional ovarian stimulation in poor responders. 
Methods: From 2004 to 2009, 389 IVF cycles in 285 women showed poor responses (defined as either a basal FSH level ≥12 mIU/mL, or the 
number of retrieved oocytes ≤3, or serum E2 level on hCG day <500 pg/mL) were analyzed, retrospectively. In total, 119 cycles with mild ovari-
an stimulation (m-IVF) and 270 cycles with conventional ovarian stimulation (c-IVF) were included. Both groups were divided based on their 
age, into groups over and under 37 years old. 
Results: The m-IVF group was lower than the c-IVF group in the duration of stimulation, total doses of gonadotropins used, serum E2 level on 
hCG day, the number of retrieved oocytes, and the number of mature oocytes. However, there was no significant difference in the number of 
good embryos, the number of transferred embryos, the cancellation rate, or the clinical pregnancy rate. In the m-IVF group over 37 years old, 
the clinical pregnancy rate and live birth rate were higher when compared with the c-IVF group, but this result was not statistically significant. 
Conclusion: In poor responder groups, mild ovarian stimulation is more cost effective and patient friendly than conventional IVF. Therefore, we 
suggest that mild ovarian stimulation could be considered for poor responders over 37 years old. 
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Introduction
Poor ovarian response to controlled ovarian hyperstimulation (COH) 
was first described by Garcia et al. [1] in 1983, and its prevalence was 
reported to be 5-24% of patients undergoing IVF [2].
Since studies began, different authors have used different criteria 
to define poor ovarian response. In general, poor responder women 
are the patients who show the number of retrieved oocytes of ≤3 
and a peak E2 level of ≤500 pg/mL during COH for IVF. In the Europe-
an Society for Human Reproduction and Embryology/American So-
ciety for Reproductive Medicine, a consensus was reached on the 
minimal criteria needed to define poor ovarian response. Thus, to de-
fine a poor ovarian response to COH, at least two of the following three 
features must be present: 1) advanced maternal age (≥40 years) or 
any other risk factor for poor ovarian response, 2) a previous poor 
ovarian response (≤3 oocytes with a conventional stimulation pro-
tocol), 3) an abnormal ovarian reserve test [3].
Several methods have been suggested for enhancing the outcome 
of these patients, because they have high cycle cancellation rates and 
a low chance of successful pregnancy. Adjuvant therapies for COH 
such as growth hormone therapy or pyridostigmine, oral L-arginine, 
and transdermal testosterone failed to improve pregnancy rates in 
poor ovarian responders. In addition, short protocols using GnRH an-
tagonists as well as short or long protocols using GnRH agonists also 
did not show any improvements in pregnancy rates [4].
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Mild ovarian stimulation, when used for patients with normal ovari-
an response, not only decreases the incidence of ovarian hyperstimu-
lation syndrome (OHSS), a serious unwanted complication of COH, but 
also reduces the patient’s discomfort and cost by using a lower dose 
of gonadotropin. In 2007, Baart et al. [5] reported that the number of 
retrieved oocytes by mild ovarian stimulation may be fewer, yet better 
in terms of oocyte and embryo quality. Devroey reported in 2004 that 
mild ovarian stimulation improved endometrial receptivity [6].
In some studies, poor responders received either IVF after a natural 
cycle or IVF after mild ovarian stimulation. In 2004, Kolibianakis et al. 
[7] reported lower pregnancy rates in elderly patients with high basal 
FSH levels undergoing mild ovarian stimulation. However, in vitro 
fertilization after natural cycle or mild ovarian stimulation is still cur-
rently under investigation.
In this study, we evaluated the utility of mild ovarian stimulation in 
poor responders by comparing clinical outcomes between mild ovari-
an stimulation and conventional ovarian stimulation in these patients.
Methods
1.	Study	population
This is a retrospective study including 285 infertile women who re-
sponded poorly to COH between January 2004 and June 2009. Poor 
ovarian response to COH was defined as a serum basal FSH level more 
than 12 mIU/mL, a number of retrieved oocytes not exceeding three, 
and E2 level less than 500 pg/mL on the day of hCG administration. 
Exclusion criteria of this study include the following factors: age over 
43 years old, basal FSH level exceeding 25 mIU/mL, severe male fac-
tor infertility requiring testicular sperm extraction, and preimplanta-
tion genetic diagnosis.
During the study period, 285 female poor responders underwent 
389 IVF cycles. Pregnancy rates, live birth rates, as well as clinical utili-
ty were compared between cycles with mild ovarian stimulation (m-
IVF), the study group, and cycles with conventional ovarian stimula-
tion (c-IVF), the control group. In order to compare differences in re-
sponse according to age, poor responders were further divided into 
two groups by an age cutoff of 37 years old, because follicular count 
reduces rapidly after that age.
2.	Study	design
1)	Controlled	ovarian	hyperstimulation
An ovarian hyperstimulation protocol was initiated after confirm-
ing the lack of any growing follicle greater than 10 mm in diameter 
by ultrasound, and basal serum E2 not exceeding 50 pg/mL on day 2 
or 3 of the menstrual cycle.
Ovarian hyperstimulation was achieved either by short or long pro-
tocols using GnRH agonist leuprolide (Lucrin®, Abott Korea Ktd., Seoul, 
Korea) or short protocols using 0.25 mg GnRH antagonists (Cetro-
tide®, Merck Serno, Geneva, Switzerland or Orgalutran® Schering-
Plough Organon, Oss, the Netherlands).
In the m-IVF group, patients were either given 100 mg of clomi-
phene citrate (Clomiphene®, Youngpoong Pharma, Seoul, Korea) or 5 
mg letrozole (Femara®, Novartis, East Hanover, NJ, USA) daily for five 
days, or no medication, followed by administration of 150-225 IU of 
either recombinant FSH (Gonal-F®, Merck Serno) or human meno-
pausal gonadotropin (human menopausal gonadotropin, Menopur®, 
Ferring Pharmaceuticals Korea Co. Ltd., Seoul, Korea) daily (Figure 1). 
In the c-IVF group, more than 300 IU of FSH or hMG were given.
2)	Oocyte	retrieval	and	embryo	transfer
For follicular maturation, 250 μg of recombinant hCG (Ovidrel®, Mer-
ck Serno) was injected subcutaneously when a dominant follicle 
reached 18 mm in diameter. Oocytes were retrieved approximately 
34-36 hours after hCG administration. Depending on the quality of 
the sperms retrieved, either conventional IVF or ICSI was used to fer-
tilize eggs. 
After an incubation period of two or three days, good quality em-
bryos were selected and transferred into the uterine cavity. Luteal 
support for those who had embryos transferred, either 50 mg injec-
tion of progesterone (Progesteron®, Watson Pharmaceuticals Inc., 
Morristown, NJ, USA) or 400 mg transvaginal progesterone (Yena-
tron®, Acraf S.p.A., Roma, Italy) were administered.
3)	Confirmation	of	pregnancy
Clinical pregnancy was confirmed by a serum β-hCG level on the 
12th day from ovum pickup measuring at least 5 mIU/mL, and the 
presence of a gestational sac in the follow-up ultrasound at 5-6 weeks 
of gestational age. Abortion was defined as fetal loss before 20 weeks 
gestation despite the presence of a gestational sac in the first trimes-
ter ultrasound.
3.	Statistical	analysis
Statistical analysis was performed with SPSS ver. 12.0 (SPSS Inc. Chi-
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Figure	1. Schematic diagram of mild ovarian stimulation. www.eCERM.org
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cago, IL, USA). A student’s t-test and chi-square test were performed 
for data analysis. A p-value of less than 0.05 was considered to be sta-
tistically significant. 
Results
Of the total 389 cycles of IVF performed on poor responders, 119 
cycles were mild ovarian stimulation cycles, and 270 cycles were con-
ventional ovarian stimulation cycles.
Table 1. compares the two groups’ clinical features. The number of 
previous IVF cycles was significantly higher in the study group, where-
as there were no differences in age, body mass index, duration of in-
fertility, cause of infertility, or basal FSH levels. The total number of 
doses of gonadotropin used during hyperstimulation was significant-
ly lower in the study group than in the control group (901.6±587.0 
IU vs. 3,165.6±1,459.2 IU, p<0.001). Similarly, the total stimulation 
period (8.5±2.9 days vs. 10.1±2.7 days, p<0.001) was significantly 
shorter in the study group. The endometrial thickness was signifi-
cantly thicker in the control group on the day of hCG administration 
(10.1±2.7 mm vs. 8.1±2.2 mm).
The total number of oocytes retrieved and the number of oocytes 
that matured were each significantly fewer in the study group. How-
ever, there were no differences in the fertilization rates, number of 
transferred embryos, or number of good quality embryos between 
the two groups (Table 2). Although clinical pregnancy rates per initi-
ated cycle and per transferred cycle in the control group (14.8% and 
22.6%, respectively) were higher than in the study group (11.8% and 
18.4%, respectively), these values were not statistically significant. 
Similarly, live birth rates per initiated cycle and per transferred cycle 
were higher in the control group (11.5% and 17.5%, respectively) than 
in the study group (6.7% and 10.5%, respectively), but did not show 
statistical significance.
Clinical pregnancy rates and live birth rates in patients below age 
37 showed decreased values in the study group, regardless of the 
rates per initiated cycle or per transferred cycle. However, this also 
failed to show statistical significance. On the other hand, in the sub-
group of patients over age 37, these values were higher in the study 
group than in the control group; however, there was no statistical 
significance (Table 3).
Discussion
It has been reported in a number of studies that mature oocyte 
counts of 5-15 may lead to a good clinical outcome of IVF, and fur-
thermore, oocyte counts of less than 5 predict significantly reduced 
clinical pregnancy rates as well as live birth rates compared to the 
normal response group [8,9]. Many possible methods have been pro-
posed to improve pregnancy rates for such poor responders, yet none 
has been very promising to date.
In 1996, Land et al. [10] showed an increase in follicular count and 
the number of retrieved oocytes in a group of poor responders who 
had received 450 IU of hMG daily, compared to a group that received 
Table	1. Basal characteristics of IVF patients undergoing mild ovarian 
stimulation and conventional ovarian stimulation
m-IVF group c-IVF group p-value
Total No. of cycles 119 270
Age (yr) 36.7±3.7 36.2±3.8 NS
Body mass index (kg/m²) 21.5±2.9 21.4±2.8 NS
Duration of infertility (mo) 42.8±34.0 52.3±39.9 NS
No. of previous IVF cycles 3.3±2.6 2.6±2.0 <0.01
Basal FSH (mIU/mL) 16.2±3.9 16.3±3.6 NS
Infertility causes
 Tubal factor (%) 16.8 21.5
 Male factor (%) 8.4 10.4
 Ovulatory factor (%) 47.9 38.9
 Endometriosis (%)  11.8 15.2
 Unexplained (%) 15.1 14.1
The values are expressed as mean±SD.
m-IVF, mild ovarian stimulation; c-IVF, conventional ovarian stimulation; NS, 
not significant; No, number.
Table	2. IVF outcomes in patients with mild ovarian stimulation and 
conventional ovarian stimulation
m-IVF group c-IVF group p-value
Duration of stimulation (day) 8.5±2.9 10.1±2.7 <0.001
Dosage of gonadotrophins (IU) 901.6±587.0 3,165.6±1,459.2 <0.001
E2 on hCG day (pg/mL)  289.2±126.4 317.6±110.7 NS
Endometrial thickness (mm) 8.1±2.2 10.1±2.3 <0.01
No. of retrieved oocytes 1.5±0.9 1.9±1.0 <0.01
No. of mature oocytes 1.6±0.7 1.9±0.8 <0.01
Fertilization rate (%) 73.1 69.7 NS
No. of transferred embryos 1.5±0.8 1.6±0.7 NS
Cycle cancellation rate (%) 36.1 (43/119) 34.4 (93/270) NS
hCG positive rate (%) 17.6 (21/119) 20.7 (56/270) NS
Biochemical pregnancy rate (%) 5.9 (7/119) 5.6 (15/270) NS
No. of ectopic pregnancy 0 1
Follow-up loss 0 1
Miscarriage rate (%) 5.0 (6/119) 3.0 (8/270) NS
Implantation rate (%) 14.7 15.6 NS
Clinical pregnancy rate
   Per initiated cycles (%) 11.8 (14/119)  14.8 (40/270) NS
   Per transferred cycles (%) 18.4 (14/76) 22.6 (40/177) NS
Live birth rate
   Per initiated cycles (%) 6.7 (8/119) 11.5 (31/270) NS
   Per transferred cycles (%) 10.5 (8/76) 17.5 (31/177) NS
The values are expressed as mean±SD.
m-IVF, mild ovarian stimulation; c-IVF, conventional ovarian stimulation; NS, 
not significant; No, number.  http://dx.doi.org/10.5653/cerm.2011.38.3.159
  Clin Exp Reprod Med 2011;38(3):159-163
162
225 IU. However, the number of embryos was similar between the 
two groups, and the clinical pregnancy rate was unexpectedly lower 
in the group that received 450 IU. As a high dose gonadotropin does 
not increase the number of embryos nor improve pregnancy rates, a 
low-dose-gonadotropin administration protocol has emerged, which 
has not only retained pregnancy rates but has also saved costs.
Mild ovarian stimulation in normal ovarian response groups is 
known to be a patient-friendly method that reduces the incidence of 
ovarian hyperstimulation syndrome, and at the same time, reduces 
unnecessary discomfort to patients by using a lower dose of gonado-
tropin, and also reduces medical expenses [11]. Many studies have 
reported that mild ovarian stimulation, compared to conventional 
ovarian stimulation, improves embryo quality and implantation rates. 
Recently, it has been suggested that mild ovarian stimulation could 
reduce the proportion of mosaic embryos and aneuploidies [12]. 
While many investigators have investigated the usefulness of mild 
ovarian stimulation, few studies have focused on mild ovarian stimu-
lation in poor responders.
In this study on poor responders, similar to the results shown in oth-
er studies on normal responders, the number of retrieved oocytes 
and matured oocytes were significantly lower in the mild ovarian 
stimulation group than in the conventional ovarian stimulation group. 
There was no significant difference in the number of good quality 
embryos, fertilization rates, or the number of transferred embryos 
between two groups. This implies that when a mild ovarian stimula-
tion protocol was applied in the poor responders, despite a small 
number of retrieved oocytes, good quality embryos were produced 
that improved the fertilization rate, clinical pregnancy rate, and live 
birth rate. This was particularly true in the subgroup of women aged 
37 or more, which in study group, showed higher pregnancy rates 
and live birth rates than control group. Judging by these results, a 
high dose gonadotropin protocol failed to prove its usefulness in IVF 
procedures on patients over 37 years of age [13]. However, in this 
study, pregnancy rates were lower in the study group than was ex-
pected for the general population, and this may be due to differenc-
es in numbers of previous IVF procedures and differences in endo-
metrial thickness.
Patients in the study group had previously undergone several more 
cycles of IVF procedures, and this may have resulted in lowered clini-
cal pregnancy rates and live birth rates. Comparing the number of 
cycles undergone until the first IVF, the study group was 6.7%, 18 cy-
cles, whereas the control group was 75.6%, 96 cycles, and the differ-
ence was statistically significant. It may be reflected that clinicians 
have a tendency to avoid mild ovarian stimulation in women with 
the first cycle. The reason for this is that although mild ovarian stimu-
lation can yield results as good as conventional ovarian stimulation, 
many studies report higher cycle cancellation rates [14].
Furthermore, the endometrial thickness on ultrasound measured 
thinner on the day of hCG administration in the study group than in 
the control group. This is because in the control group, the clomi-
phene-gonadotropin combination method was used in 7 cycles 
(4.1%), whereas in the study group, it was used in 91 cycles (76.5%). 
Clomiphene is known to cause endometrial thinning in 15-50% of 
patients due to the antiestrogenic effect of the compound itself, and 
unfortunately, result in a lower pregnancy rate [15]. Thin endometri-
um has been shown to affect pregnancy rates in previous studies. 
The preovulatory endometrium is important in achieving pregnancy, 
and in 1993, Dickey et al. [16] found that when the preovulatory en-
dometrium is thinner than 6 mm, pregnancy is virtually impossible, 
and when it is thinner than 8 mm, there is an increased risk of preclin-
ical miscarriage. Also, we observed that endometrial thickness was 
thinner for those undergoing the clomiphene-gonadotropin combi-
Table	3. IVF outcomes in patients with mild ovarian stimulation and conventional ovarian stimulation according to age 
≤37 years old >37 years old
m-IVF c-IVF
a p-value m-IVF c-IVF
b p-value
Total No. of cycles 58 151 61 119
hCG positive rate (%) 24.1 (14/58) 29.1 (44/151) NS 11.5 (7/61) 10.1 (12/119) NS
Biochemical pregnancy rate (%) 6.9 (4/58) 6.0 (9/151) NS 4.9 (3/61) 5.0 (6/119)
Miscarriage rate (%) 6.9 (4/58) 3.3 (5/151) NS 3.3 (2/61) 2.5 (3/119) NS
Implantation rate (%) 19.4 24.1 NS 8.2 4.8 NS
Clinical pregnancy rate
   Per initiated cycles (%) 17.2 (10/58) 22.5 (34/151) NS 6.6 (4/61) 5.0 (6/119) NS
   Per transferred cycles (%) 23.3 (10/43) 33.0 (34/103) NS 12.1 (4/33) 8.1 (6/74) NS
Live birth rate
   Per initiated cycles (%) 10.3 (6/58) 19.2 (29/151) NS 3.3 (2/61) 1.7 (2/119) NS
   Per transferred cycles (%) 14.0 (6/43) 28.2 (29/103) NS 6.1 (2/33) 2.7 (2/74) NS
m-IVF, mild ovarian stimulation; c-IVF, conventional ovarian stimulation; No, number; NS, not significant. 
aInclude 1 ectopic pregnancy; 
bInclude 1 follow-up loss.www.eCERM.org
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nation method than the letrozol-gonadotropin combination method 
(7.6 mm vs. 9.5 mm, p<0.01). Therefore, the clinical pregnancy rate 
was lower with the clomiphene-gonadotropin combination method 
than the letrozol-gonadotropin combination method.
In summary, for poor responders with high basal FSH, mild ovarian 
stimulation resulted in IVF outcomes similar to conventional ovarian 
stimulation. In poor responders older than 37 years old in particular, 
mild ovarian stimulation yielded slightly better pregnancy rates than 
conventional ovarian stimulation. Mild ovarian stimulation can save 
costs by using a smaller amount of gonadotropin and can reduce pa-
tients’ burden of undergoing frequent injections. In conclusion, in 
terms of embryo quality, pregnancy rate, and cost effectiveness, mild 
ovarian stimulation is a promising alternative to conventional ovarian 
stimulation for poor ovarian responders.
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